Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patientsâ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a pipeline of three independent, rare disease endocrinology product candidates in clinical development, and has established oncology as its second therapeutic area of focus. Source
No articles found.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...
Reata is a clinical-stage biopharmaceutical com...
TruBrain is a leading brand in high-performance cognitive nutrition with over $11....
TruBrain is a leading brand in high-performance...
SelenBio, Inc is a biotechnology company specializing in the prevention of bacteri...
SelenBio, Inc is a biotechnology company specia...
Aldeyra Therapeutics is a biotechnology company devoted to developing and commerci...
Aldeyra Therapeutics is a biotechnology company...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the d...
Viking Therapeutics is a clinical-stage biophar...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...
Join the National Investor Network and get the latest information with your interests in mind.